Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLN12140 in Adult Patients With Primary IgA Nephropathy
NCT07553494Phase 2Not yet recruiting
- Sponsor
- Linno Pharmaceuticals
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing SLN12140 with Placebo (2 arms). Primary endpoint: Urine protein-to-creatinine ratio at 36 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
SLN12140
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07553494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553494.